IN2014CN04127A - - Google Patents
Download PDFInfo
- Publication number
- IN2014CN04127A IN2014CN04127A IN4127CHN2014A IN2014CN04127A IN 2014CN04127 A IN2014CN04127 A IN 2014CN04127A IN 4127CHN2014 A IN4127CHN2014 A IN 4127CHN2014A IN 2014CN04127 A IN2014CN04127 A IN 2014CN04127A
- Authority
- IN
- India
- Prior art keywords
- formula
- triazol
- 115the
- benzamide
- pharmaceuticals
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IB2011054976 | 2011-11-08 | ||
| PCT/IB2012/056218 WO2013068935A1 (en) | 2011-11-08 | 2012-11-07 | 2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2-yl)picolinamide derivatives as orexin receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014CN04127A true IN2014CN04127A (de) | 2015-07-10 |
Family
ID=47258050
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN4127CHN2014 IN2014CN04127A (de) | 2011-11-08 | 2012-11-07 |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US9150566B2 (de) |
| EP (1) | EP2776430B1 (de) |
| JP (1) | JP5718535B2 (de) |
| KR (1) | KR101676930B1 (de) |
| CN (1) | CN103917538B (de) |
| AR (1) | AR088692A1 (de) |
| AU (1) | AU2012335194B2 (de) |
| BR (1) | BR112014010617B1 (de) |
| CA (1) | CA2846568C (de) |
| CL (1) | CL2014000659A1 (de) |
| CY (1) | CY1117638T1 (de) |
| DK (1) | DK2776430T3 (de) |
| EA (1) | EA024106B1 (de) |
| ES (1) | ES2572703T3 (de) |
| HK (1) | HK1199022A1 (de) |
| HR (1) | HRP20160678T1 (de) |
| HU (1) | HUE029239T2 (de) |
| IL (1) | IL232462A (de) |
| IN (1) | IN2014CN04127A (de) |
| MX (1) | MX343837B (de) |
| MY (1) | MY167791A (de) |
| PL (1) | PL2776430T3 (de) |
| SG (1) | SG11201401665WA (de) |
| SI (1) | SI2776430T1 (de) |
| TW (2) | TWI555747B (de) |
| UA (1) | UA112317C2 (de) |
| WO (1) | WO2013068935A1 (de) |
| ZA (1) | ZA201404189B (de) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9440982B2 (en) | 2012-02-07 | 2016-09-13 | Eolas Therapeutics, Inc. | Substituted prolines/piperidines as orexin receptor antagonists |
| BR112014019426A8 (pt) | 2012-02-07 | 2017-07-11 | Eolas Therapeutics Inc | Prolinas/ piperidinas substituídas como antagonistas do receptor de orexina |
| CA2873341C (en) | 2012-06-04 | 2018-01-02 | Actelion Pharmaceuticals Ltd | Benzimidazole-proline derivatives |
| CN105051040A (zh) | 2013-03-12 | 2015-11-11 | 埃科特莱茵药品有限公司 | 作为食欲素受体拮抗剂的氮杂环丁烷酰胺衍生物 |
| NZ721438A (en) | 2013-12-03 | 2021-12-24 | Idorsia Pharmaceuticals Ltd | Crystalline form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists |
| UA119151C2 (uk) | 2013-12-03 | 2019-05-10 | Ідорсія Фармасьютікалз Лтд | КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА |
| KR102330133B1 (ko) | 2013-12-04 | 2021-11-23 | 이도르시아 파마슈티컬스 리미티드 | 벤즈이미다졸-프롤린 유도체의 용도 |
| WO2015087853A1 (ja) * | 2013-12-13 | 2015-06-18 | 大正製薬株式会社 | オキサジナン化合物の結晶形及びその製造方法 |
| JP2017024990A (ja) * | 2013-12-13 | 2017-02-02 | 大正製薬株式会社 | オキサゾリジン及びオキサジナン誘導体 |
| EP3143999A4 (de) * | 2014-05-16 | 2017-12-20 | The University of Tokyo | Behandlungsmittel gegen depressionen |
| WO2016025669A1 (en) | 2014-08-13 | 2016-02-18 | Eolas Therapeutics, Inc. | Difluoropyrrolidines as orexin receptor modulators |
| WO2016095205A1 (en) | 2014-12-19 | 2016-06-23 | Merck Sharp & Dohme Corp. | Heteroaryl orexin receptor antagonists |
| CN104557744B (zh) * | 2014-12-23 | 2017-04-12 | 广东东阳光药业有限公司 | 一种三氮唑化合物的制备方法 |
| CN106749269B (zh) | 2015-11-23 | 2019-01-04 | 广东东阳光药业有限公司 | 八氢吡咯并[3,4-c]吡咯衍生物及其用途 |
| BR112018016446B1 (pt) | 2016-02-12 | 2024-02-06 | Eolas Therapeutics, Inc. | Composto de piperidina halo-substituída, composição farmacêutica compreendendo dito composto e uso terapêutico dos mesmos |
| MX2019012902A (es) | 2017-05-03 | 2019-12-16 | Idorsia Pharmaceuticals Ltd | Preparacion de derivados de acido 2-([1,2,3]triazol-2-il)-benzoico . |
| WO2020099511A1 (en) * | 2018-11-14 | 2020-05-22 | Idorsia Pharmaceuticals Ltd | Benzimidazole-2-methyl-morpholine derivatives |
| GB201901142D0 (en) * | 2019-01-28 | 2019-03-20 | Heptares Therapeutics Ltd | OX1 Antagonists |
| CN116724037A (zh) | 2021-02-02 | 2023-09-08 | 爱杜西亚药品有限公司 | (4-甲基-2-[1,2,3]三唑-2-基-苯基)-[(r)-3-(3-[1,2,3]三唑-2-基-苄基)-吗啉-4-基]-甲酮的结晶形式 |
| TW202400149A (zh) * | 2022-05-13 | 2024-01-01 | 瑞士商愛杜西亞製藥有限公司 | 經噻唑并芳基-甲基取代之環狀肼-n-甲醯胺衍生物 |
| CN115947697A (zh) * | 2022-12-28 | 2023-04-11 | 苏州汉德创宏生化科技有限公司 | 一种3-氧代吗啉-4-羧酸叔丁酯的合成方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5130432A (en) | 1990-12-21 | 1992-07-14 | Syntex (U.S.A.) Inc. | Process for preparing cyclic amines and intermediate products thereof |
| EP0591426A4 (en) | 1991-06-27 | 1996-08-21 | Univ Virginia Commonwealth | Sigma receptor ligands and the use thereof |
| EP1435955A2 (de) * | 2001-05-05 | 2004-07-14 | SmithKline Beecham P.L.C. | N-aroyl-zyklisches amin-derivat als orexin-rezeptor-antagonisten |
| US7470710B2 (en) | 2001-06-28 | 2008-12-30 | Smithkline Beecham P.L.C. | N-aroyl cyclic amine derivatives as orexin receptor antagonists |
| GB0115862D0 (en) * | 2001-06-28 | 2001-08-22 | Smithkline Beecham Plc | Compounds |
| GB0124463D0 (en) * | 2001-10-11 | 2001-12-05 | Smithkline Beecham Plc | Compounds |
| GB0130335D0 (en) * | 2001-12-19 | 2002-02-06 | Smithkline Beecham Plc | Compounds |
| PL1751111T3 (pl) | 2004-03-01 | 2015-06-30 | Actelion Pharmaceuticals Ltd | Podstawione pochodne 1,2,3,4-tetrahydroizochinoliny |
| EP1998774A1 (de) | 2006-03-15 | 2008-12-10 | Actelion Pharmaceuticals Ltd. | Tetrahydroisochinolin-derivate zur verstärkung der gedächtnisfunktion |
| JP2009543785A (ja) | 2006-07-14 | 2009-12-10 | メルク エンド カムパニー インコーポレーテッド | 架橋ジアゼパンオレキシン受容体アンタゴニスト |
| GB0620818D0 (en) | 2006-10-19 | 2006-11-29 | Ucb Sa | Therapeutic agents |
| PE20081229A1 (es) | 2006-12-01 | 2008-08-28 | Merck & Co Inc | Antagonistas de receptor de orexina de diazepam sustituido |
| JP2010540429A (ja) | 2007-09-24 | 2010-12-24 | アクテリオン ファーマシューティカルズ リミテッド | オレキシン受容体拮抗薬としてのピロリジン類及びピペリジン類 |
| PE20091010A1 (es) | 2007-10-10 | 2009-08-08 | Actelion Pharmaceuticals Ltd | Derivados de tetrahidroquinolina |
| WO2010048012A1 (en) | 2008-10-21 | 2010-04-29 | Merck Sharp & Dohme Corp. | 2,5-disubstituted piperidine orexin receptor antagonists |
| US8466281B2 (en) * | 2008-10-21 | 2013-06-18 | Merck Sharp & Dohme Corp. | 2,5-disubstituted morpholine orexin receptor antagonists |
| WO2010048010A1 (en) * | 2008-10-21 | 2010-04-29 | Merck Sharp & Dohme Corp. | 2,5-disubstituted piperidine orexin receptor antagonists |
| US8133908B2 (en) | 2008-12-02 | 2012-03-13 | Glaxo Group Limited | Heteroaryl derivatives of N-{[(1S,4S,6S)-3-(2-pyridinylcarbonyl)-3-azabicyclo[4.1.0]hept-4-yl]methyl}-2-amine |
| MX2011005800A (es) | 2008-12-02 | 2011-06-20 | Glaxo Group Ltd | Derivados de n{[(1r,4s,6r)-3-(2-piridinilcarbonil)-3-azabiciclo[4. 1.0]hept-4-il]metil}-2-heteroarilamina y sus usos. |
| WO2011050200A1 (en) | 2009-10-23 | 2011-04-28 | Janssen Pharmaceutica Nv | Fused heterocyclic compounds as orexin receptor modulators |
| PL3093291T3 (pl) | 2009-10-23 | 2019-11-29 | Janssen Pharmaceutica Nv | Dipodstawione oktahydropirolo[3,4-c]pirole jako modulatory receptora oreksyny |
| WO2011050202A1 (en) | 2009-10-23 | 2011-04-28 | Janssen Pharmaceutica Nv | Fused heterocyclic compounds as orexin receptor modulators |
-
2012
- 2012-11-07 AU AU2012335194A patent/AU2012335194B2/en not_active Ceased
- 2012-11-07 DK DK12791862.1T patent/DK2776430T3/en active
- 2012-11-07 IN IN4127CHN2014 patent/IN2014CN04127A/en unknown
- 2012-11-07 TW TW101141421A patent/TWI555747B/zh not_active IP Right Cessation
- 2012-11-07 ES ES12791862.1T patent/ES2572703T3/es active Active
- 2012-11-07 SI SI201230556A patent/SI2776430T1/sl unknown
- 2012-11-07 CN CN201280054325.7A patent/CN103917538B/zh active Active
- 2012-11-07 PL PL12791862.1T patent/PL2776430T3/pl unknown
- 2012-11-07 JP JP2014540606A patent/JP5718535B2/ja active Active
- 2012-11-07 MX MX2014005635A patent/MX343837B/es active IP Right Grant
- 2012-11-07 WO PCT/IB2012/056218 patent/WO2013068935A1/en active Application Filing
- 2012-11-07 KR KR1020147014960A patent/KR101676930B1/ko active IP Right Grant
- 2012-11-07 AR ARP120104193A patent/AR088692A1/es active IP Right Grant
- 2012-11-07 MY MYPI2014701155A patent/MY167791A/en unknown
- 2012-11-07 CA CA2846568A patent/CA2846568C/en active Active
- 2012-11-07 BR BR112014010617-7A patent/BR112014010617B1/pt not_active IP Right Cessation
- 2012-11-07 UA UAA201402001A patent/UA112317C2/uk unknown
- 2012-11-07 US US14/357,159 patent/US9150566B2/en active Active
- 2012-11-07 EA EA201400553A patent/EA024106B1/ru not_active IP Right Cessation
- 2012-11-07 HU HUE12791862A patent/HUE029239T2/en unknown
- 2012-11-07 SG SG11201401665WA patent/SG11201401665WA/en unknown
- 2012-11-07 EP EP12791862.1A patent/EP2776430B1/de active Active
- 2012-11-07 TW TW105118634A patent/TWI565703B/zh active
-
2014
- 2014-03-18 CL CL2014000659A patent/CL2014000659A1/es unknown
- 2014-05-05 IL IL232462A patent/IL232462A/en active IP Right Grant
- 2014-06-06 ZA ZA2014/04189A patent/ZA201404189B/en unknown
- 2014-12-11 HK HK14112452.0A patent/HK1199022A1/zh not_active IP Right Cessation
-
2016
- 2016-06-14 HR HRP20160678TT patent/HRP20160678T1/hr unknown
- 2016-06-15 CY CY20161100527T patent/CY1117638T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014CN04127A (de) | ||
| MX354102B (es) | Derivados de bencimidazol-prolina. | |
| UA108926C2 (ru) | LibreOffice? [2,3-D] +" +" !+ | |
| MX2011011428A (es) | Derivados de acido sulfamoilbenzoico como antagonistas de trpm8. | |
| PH12014502363A1 (en) | N-aryltriazole compounds as lpar antagonists | |
| PH12014502789A1 (en) | N-alkyltriazole compounds as lpar antagonists | |
| ATE483707T1 (de) | 2-cyclopropylthiazolderivate | |
| MX2021004000A (es) | Derivados de piperidina. | |
| TN2012000371A1 (en) | Pyrazole compounds as crth2 antagonists | |
| WO2013004995A8 (en) | Pyrimidinone compounds and their use | |
| MX2010001338A (es) | Derivados de pirimidina y piridina y su uso y composiciones farmaceuticas. | |
| SG195106A1 (en) | Trpv4 antagonists | |
| PH12014502364A1 (en) | Substituted pyrazole compounds as lpar antagonists | |
| WO2013190508A3 (en) | 1-[m-carboxamido(hetero)aryl-methyl]-heterocyclyl-carboxamide derivatives | |
| PH12015502632A1 (en) | Cxcr7 receptor modulators | |
| TN2016000061A1 (en) | Amide derivatives as lysophosphatidic acid receptor antagonists | |
| WO2011138265A3 (en) | Indole and indazole derivatives as orexin receptor antagonists | |
| EA201300857A1 (ru) | Пиразолы в качестве антагонистов crth2 | |
| MX2009007429A (es) | Compuestos de piridina y su uso como antagonistas de p2y12. | |
| PH12016501625A1 (en) | Substituted cyclopentanes, tetrahydrofuranes and pyrrolidines as orexin receptor antagonists | |
| WO2010131192A3 (en) | Novel oxazolidinone derivatives and their use as orexin receptor antagonists | |
| UA112586C2 (uk) | Похідні бензімідазолпроліну | |
| MX356499B (es) | Derivados de heteroarilamida novedosos que tienen propiedades antiandrogénicas. |